- Home
- ECO vs APLT Comparison
ECO vs APLT Comparison
Compare ECO & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECO
- APLT
- Stock Information
- Founded
- ECO 2018
- APLT 2016
- Country
- ECO Greece
- APLT United States
- Employees
- ECO N/A
- APLT N/A
- Industry
- ECO
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- ECO
- APLT Health Care
- Exchange
- ECO Nasdaq
- APLT Nasdaq
- Market Cap
- ECO 699.6M
- APLT 44.0M
- IPO Year
- ECO N/A
- APLT 2019
- Fundamental
- Price
- ECO $23.07
- APLT $0.42
- Analyst Decision
- ECO Strong Buy
- APLT Buy
- Analyst Count
- ECO 1
- APLT 7
- Target Price
- ECO $40.00
- APLT $6.10
- AVG Volume (30 Days)
- ECO 138.9K
- APLT 2.7M
- Earning Date
- ECO 08-08-2025
- APLT 08-06-2025
- Dividend Yield
- ECO 9.59%
- APLT N/A
- EPS Growth
- ECO N/A
- APLT N/A
- EPS
- ECO 2.48
- APLT N/A
- Revenue
- ECO $362,254,143.00
- APLT $265,000.00
- Revenue This Year
- ECO N/A
- APLT $1,768.13
- Revenue Next Year
- ECO $3.94
- APLT $292.85
- P/E Ratio
- ECO $9.33
- APLT N/A
- Revenue Growth
- ECO N/A
- APLT N/A
- 52 Week Low
- ECO $17.91
- APLT $0.30
- 52 Week High
- ECO $35.64
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- ECO 50.22
- APLT 60.22
- Support Level
- ECO $22.73
- APLT $0.32
- Resistance Level
- ECO $24.02
- APLT $0.36
- Average True Range (ATR)
- ECO 0.53
- APLT 0.04
- MACD
- ECO 0.08
- APLT 0.01
- Stochastic Oscillator
- ECO 59.02
- APLT 88.67
About ECO Okeanis Eco Tankers Corp.
Okeanis Eco Tankers Corp owns and operates tanker vessels in Greece. The business of the company is to own, charter out, and operate tanker vessels. The company owns, through its vessel-owning subsidiaries, a fleet of around seven tanker vessels and has around eight tanker vessels on order. The sailing fleet consists of around six modern Suezmax tankers and eight VLCC tankers.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.